On June 6, 2023, NovoCure presented the results of the LUNAR study at the annual meeting of the American Society of Clinical Oncology that revealed the that the data set in the study was faulty because it only included a small subgroup of patients whose treatment included immune checkpoint inhibitors—a standard treatment for non-small cell lung cancer. On this news, the price of NovoCure's stock fell $35.51 per share, or 43.04%, to close at $47.00 on extraordinarily high trading volume. About Lieff Cabraser Lieff Cabraser Heimann & Bernstein, LLP, with over 120 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Recognized as a "Plaintiffs' Powerhouse" by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $129 billion in verdicts and settlements.